Targeting the elabela/apelin-apelin receptor axis as a novel therapeutic approach for hypertension

Jiawei Song1, Jianqiong Tang2, Zhenzhou Zhang1

  • 1Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.

Chinese Medical Journal
|October 5, 2021
PubMed

Insights

The elabela/apelin-apelin receptor (APJ) axis plays a key role in regulating blood pressure and cardiovascular health. Targeting this axis offers a promising therapeutic strategy for hypertension and related cardiovascular diseases.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Pharmacology

Background:

  • Hypertension is a major global health risk, linked to cardiovascular and cerebrovascular complications.
  • The renin-angiotensin system and the elabela/apelin-apelin receptor (APJ) axis are implicated in hypertension.
  • The elabela/apelin-APJ axis counterbalances angiotensin II and influences nitric oxide signaling.

Purpose of the Study:

  • To review the physiology, biochemistry, and actions of the elabela/apelin-APJ axis.
  • To highlight the axis's role in hypertension and associated cardiovascular dysfunction.
  • To explore therapeutic strategies targeting the elabela/apelin-APJ axis for hypertension.

Main Methods:

  • Literature review focusing on the elabela/apelin-APJ axis in cardiovascular contexts.
  • Analysis of studies investigating the axis's role in blood pressure regulation and vascular tone.
  • Examination of loss-of-function and gain-of-function studies.

Main Results:

  • The elabela/apelin-APJ axis regulates blood pressure, vascular tone, and cardiovascular function.
  • It exerts beneficial effects on angiogenesis, cellular processes, and cardiovascular remodeling in hypertension.
  • Its precise vascular effects can vary by vessel type and pathological conditions.

Conclusions:

  • The elabela/apelin-APJ axis is critical in mitigating hypertension and cardiovascular injury.
  • It serves as a potential biomarker and therapeutic target for hypertensive diseases.
  • Further understanding of its cardiovascular actions can lead to novel hypertension interventions.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
574
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
247
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
1.8K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
911
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
284
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.7K